Abstract: Consensus interferon (CIFN) is an artifi cially engineered interferon that refl ects most of the human genotype 1 interferons and shows a higher biological and antiviral capacity in vitro. It has been used internationally to treat patients with chronic hepatitis C (HCV) infection before pegylated IFN became available. To mimic the half-life of PEG-IFN it has to be administered on a daily basis. The gold standard in the treatment of hepatitis C is well established and recommended. Today patients are being treated with a combination therapy of pegylated IFN and ribavirin. Length and dosage of therapy depends on the genotype of the virus. Patients with genotype 1 and 4 and high viral load should be treated for 48 weeks; for patients with these genotypes along with either low viral load or early virological response, therapy for 24 weeks is suffi cient. Patients with genotype 2 and 3 should be treated for up to 24 weeks. However, daily dosing of IFN-α, eg, CIFN, resulting in a higher cumulative dosage, might be benefi cial and more effi cacious in some chronic HCV-infected patients. Patients with genotype 1, having initially high viral load (Ͼ800,000 IU/mL) and showing advanced liver disease with progressive fi brosis or even cirrhosis comprise the diffi cult-to-treat in order to overcome the infection. This review summarizes and critically discusses the published data on the treatment of HCV with CIFN.
Background
Under physiological conditions, interferon-α (IFN-α) is a key cytokine produced by virtually all cells in the mammalian organism in response to a variety of bacterial and viral stimuli. In response to viral infection, IFN-α produced by the infected target cells induces a number of cellular genes involved in inhibition of viral replication. In addition, IFN-α is secreted by stimulated NK-cells and T-cells, and exerts a multitude of immune stimulatory effects of innate and adaptive immunity (Pestka 1997) . Examples of IFN-stimulated gene products include 2'5'oligoadenylate synthetase (2'5'OAS) and ß2-microglobulin.
The current standard to treat patients with chronic hepatitis C (HCV) infection is IFN-α with or without ribavirin, and great advances have been achieved (Cornberg et al 2002) . So far 2 allelic α-2 species, IFN-α-2a and IFN-α-2b, have been used. Introduction of pegylated IFN in 2001 showed a slight increase in the overall sustained virological response rates (approximately 55%) compared with conventional IFN-α (36%) (Manns et al 2001; Fried et al 2002) . However, recent studies showed that these response rates depend on several factors, including HCV genotype, baseline viral load, ethnicity, body weight and presence of advanced liver disease (Manns et al 2001) . More than 75% of patients in western Europe are infected with genotype 1 showing a high viral load and these patients are so called "diffi cult to treat" and therefore remain at risk not to respond to standard HCV treatment (Di Bisceglie and Hoofnagle 2002) . There is still a need for improved therapies, especially for diffi cult to treat patients such as HCV-genotype 1 infected individuals, patients with liver cirrhosis, or patients of any genotype who did not respond to a previous IFN-α-based therapy (Shiffman 2004) . Even the new standard therapy of pegylated IFN-α (PEG-IFN-α) in combination with ribavirin is not very effective for the so called non-responder patients. Relapsed patients may benefi t from retreatment but patients with HCV-genotype 1 who were true non-responders to IFN and ribavirin demonstrated only 12% sustained virological response (SVR) with PEG-IFN and ribavirin as second-line therapy (Shiffman 2004; Poynard et al 2005) . However, viral eradication should be still the fi rst achievable goal whenever possible.
IFN-alfacon-1
IFN-alfacon-1, a non-natural recombinant interferon, is a second-generation cytokine that was engineered to contain the most frequently occurring amino acids among the non-allelic IFN-α subtypes in humans (Blatt et al 1996) to form a consensus molecule. In rhesus monkey LLC cell line and golden Syrian hamster BHK cell line in vitro studies have shown that IFN-alfacon-1 causes a more dramatic decrease of HCV-RNA compared with IFN-α-2b (Sjogren et al 2007) and showed a 10-fold higher antiviral effi cacy (Blatt et al 1996) . These studies have been confi rmed in further in vivo studies.
Because the serum levels of consensus IFN (CIFN) given 3 times a week drops almost below the detection limit by the next dose, daily dosing of CIFN has been used in some studies (Kaiser et al 2005) . In some studies, a high initial dosing has been used as induction therapy to reduce viral load and obtain an early virological response (EVR), reasoning that this would lead to a higher SVR (Lam et al 1997) . CIFN is approved for use in the US at the dose of 15 μg and in Europe at the dose of 9 μg sc in therapy-naive HCV infected patients 3 times a week (tiw) for up to 6 months.
To date, several controlled but small studies have been published investigating the role, safety and efficacy of IFN-alfacon-1 in patients with chronic HCV who were either naïve to antiviral therapy or did not respond to antiviral combination therapy with IFN-α or PEG-IFN-α in combination with ribavirin.
However, due to economic reasons and after a merger of the former company distributing CIFN the drug has been taken off the market by the manufacturer, at least in Germany, in 2006.
Methods
This article reviews the results of recent published and preliminary studies involving IFN-alfacon-1 and ribavirin in the treatment of chronic HCV. The published literature was identifi ed using a MEDLINE/PubMed search with secondary review of cited publications. All articles have been carefully read and are critically discussed.
Results
In an early multicenter, randomized, controlled, doubleblind, phase III study with 704 patients with chronic HCV infection, Tong et al (1997) compared CIFN at doses of 3 μg and 9 μg to a standard regimen of recombinant IFN-α-2b at 15 μg 3 times weekly for 24 weeks with a 24 week follow-up period in a therapy-naïve cohort. The benefi cial effect was greater with the 9 μg dose than the 3 μg dose. The sustained alanine aminotransferase (ALT) and HCV RNA response rates were 20.3% and 12.1%, respectively, in the 9 μg CIFN cohort and 19.6% and 11.3%, respectively, in the 15 μg IFN IFN-α-2b cohorts (Tahara et al 2007) . Patients with HCV genotype-1 did respond better in the high dose CIFN cohort (24% vs 15%). Improvements in liver histology were noted in all 3 treatment groups. The adverse-event profi les were similar in all cohorts.
In a subsequent multicenter trial, a higher dose of CIFN (15 μg) was reinstituted in patients who either had relapsed or were non-responders to prior CIFN or IFN-α-2b therapy. Patients were randomized to receive 24 or 48 weeks of retreatment followed by 24 weeks of observation. The SVR were 28% in relapsers and 5% in non-responders, respectively, in the 24-week retreatment cohort and 58% and 13%, respectively, in the 48-week retreatment cohort, indicating that longer treatment in relapsers and non-responders results in a better overall response rate. The administration of 9 μg or 15 μg CIFN was well tolerated and adverse effects were similar to those of IFN-α-2b. 15 μg of CIFN provided meaningful response in both relapsers and non-responders (Keeffe and Hollinger 1997) .
In a randomized study of Pockros et al (1998) , 704 patients have been treated with CIFN. Two-hundred and thirty-two patients received 3 μg CIFN tiw, 232 patients received 9 μg CIFN tiw, and 240 patients were treated with IFN-α-2b at 3 MU tiw. Fifty-three percent of patients (120/225) who had normal ALT concentrations showed undetectable HCV RNA at the end of treatment. At the end of follow up, 47% presented a sustained virological response. In contrast, of the patients with undetectable HCV RNA, 75% (120/161) and 84% (51/61) had normal serum ALT activities at the end of treatment and post-treatment observation period, respectively. Most patients with undetectable HCV RNA had normal ALT values. In contrast, only half of the patients with normal ALT values were negative for HCV. At the end of treatment, HCV RNA response predicted sustained virological response better than did the ALT response (Pockros et al 1998) .
In a large multicenter trial, 472 patients have been treated with either CIFN or IFN-α-2b for up to 6 months. The purpose of the analysis was to compare the effi cacy parameters (eg, clearance of HCV RNA, normalization of ALT values, and improvement of histology) in non-fi brotics, fi brotics, and cirrhotics. Patients with cirrhosis and chronic HCV infection showed the same benefi t from IFN treatment as non-cirrhotic patients when effi cacy was assessed by clearance of serum HCV RNA or by histological benefi t. Sustained virological responses were similar when measured among non-fi brotic (11%), fi brotic (13%), and cirrhotic (11%) patients. Cirrhotic patients had a lower sustained ALT response rate (12%) than did non-fi brotic patients (23%). Ninety percent of nonfi brotics but only 71% of fi brotics and 67% of cirrhotics who sustained a virological response showed normalized ALT. In conclusion, liver cirrhosis should not be a reason for excluding patients from therapy, because both cirrhotic and fi brotic HCV patients benefi ted from IFN therapy, not only by clearance of the virus but by improvement in liver histology (Everson et al 1999) .
In Canada, 467 patients chronically infected with HCV were treated with either CIFN at 9 μg or 3 MU IFN-α-2b tiw. Eighteen percent of patients showed a breakthrough of HCV-RNA, and 19% showed a breakthrough of ALT. When the patients who were initially non-responders to IFN treatment were re-treated with CIFN (15 μg) for 12 months, 27% of those with viral breakthroughs had a sustained viral response compared with 8% in prior non-responders without breakthroughs. Sustained ALT responses were observed in 39% with breakthroughs compared with 10% in those without breakthroughs. Heathcote et al (1999) concluded that prior non-responders with breakthroughs have a greater chance of responding to retreatment than do non-responders without breakthrough (defi ned as re-occurrence of the virus throughout therapy). However, repeated HCV-RNA testing has to be conducted during therapy.
Genotyping has been shown to predict response to IFN, but it is expensive. HCV serotyping is less expensive and simple, and may be equally useful. In a large multicenter trial, 704 patients with chronic HCV infection treated with CIFN 3 μg, 9 μg or IFN-α-2b tiw, the end of treatment HCV RNA rate of response (defi ned as undetectable serum on two consecutive assessments) was 29% for serotype 1 vs 24% for genotype 1 after CIFN. The corresponding rates with IFN-α-2b were 14% vs 15%, respectively. Independently of treatment, patients infected with serotype or genotype 2 or 3 had a better therapeutic response than those infected with genotype 1 (Keeffe et al 1999a) .
Patients with genotype 1 showed lower response rates than those with genotype 2 and 3. In a multicenter trial, 472 patients with chronic HCV treated with either CIFN or IFN-α-2b, neither virological sustained responders nor relapsers differed in the pattern of serum HCV RNA decrease based on genotype. Relapsers had a slower rate of serum HCV RNA decrease than did virological sustained responders. HCV genotype 1 treated with CIFN had a greater decrease in HCV RNA during therapy than did patients treated with IFN-α-2b. However, there was no difference in the magnitude of serum HCV RNA decrease between the two IFN treatments for patients with genotype 2 or 3 (Keeffe et al 1999b) . Patients who relapsed after a prior treatment with CIFN at doses of either 3 or 9 μg may benefi t from a re-treatment with 15 μg.
IFN is a potent cytokine with multiple targets. From previous studies it is very well known that patients being treated with IFN-α for chronic HCV infection may develop either hypo-or hyperthyroidism with destructive thyroiditis. In a prospective Italian trial, 51 patients with chronic HCV infection and without pre-existing thyroid disease received antiviral therapy with IFN-α-2b plus ribavirin or CIFN plus ribavirin. Ten out 36 patients developed thyroid autoimmunity during therapy with IFN-α-2b. Under CIFN treatment, 5 out of 15 patients developed thyroid autoimmunity and stopped antiviral treatment. All patients did recover from thyroidism without specifi c treatment. However, CIFN may induce thyroid autoimmunity in a larger proportion compared with IFN-α-2b (Mazziotti et al 2002) .
In a small study in Brazil, 14 patients were treated with a rather high dose of CIFN of 15 μg plus ribavirin (1000 mg) daily for 4 weeks followed by 9-15 μg every second day for 44 weeks. In 10 patients where was a marked decrease of viral load at week 2, and 10 patients showed a loss of HCV RNA by the end of treatment. SVR was seen in 4 out of 11 patients (36%) who completed 24 weeks of follow up (Da Silva et al 2002) .
Patients with genotype 2 and 3 may respond better to antiviral therapy compared to genotype 1 patients. Fattovich et al (2003) determined the effi cacy and safety of different doses of CIFN plus ribavirin in the initial treatment of chronic CIFN in chronic HCV HCV infection. Patients with GT 2/3 received either 9 μg (group A) or 18 μg (group B) of CIFN tiw plus ribavirin for 24 weeks. Genoytype 1 patients were treated with 9 μg (group C) or 18 μg (Group D) for 48 weeks. In an ITT analysis, the sustained virological response at 24-week follow up was 69% and 66% for groups A and B and 40% and 36% for groups C and D. The overall SVR was 67% and 38% in patients with genotype 2/3 and 1, respectively. Therefore, a higher CIFN dose does not increase SVR.
Despite the genotype, the response to antiviral treatment depends also on a different racial and ethnic background. Three-hundred and thirty patients with chronic HCV infection were treated with CIFN as a daily induction therapy at 15 μg daily for 30 days followed by a randomized 1:1 ratio of either 9 or 15 μg every other day. Thirty percent of patients were non-white. An overall SVR was achieved in 24% of white, 12% of Hispanic, and 4% of AfricanAmerican patients. Fifteen percent of white and 13% of Hispanic genotype 1 patients achieved SVR compared with 2% of African-American. Surprisingly, a SVR of 50% and 40% was achieved in African-American and white genotype 2 patients, compared with 10% in Hispanic patients (Gaglio et al 2004) .
Combination therapy with PEG-IFN (α-2a or -2b) and ribavirin is the most effective therapy for patients with HCV infection. However, responses are less than optimal in some subgroups of patients. Viral kinetics might be useful to predict therapeutic outcome. Rapidity of virological response seems to be a better predictor than genotype and initial viral load. Weight-based dosing of ribavirin has emerged as another important consideration. This strategy seems to be the most important for diffi cult-to-treat patients with genotype 1 or advanced fi brosis, and for African Americans, and is possibly important for patients who have genotype 3 and high viral load. Re-treatment of non-responders with IFN-based therapy has been associated with low rates of sustained virological response. CIFN might offer a new option for patients who did not achieve an early treatment response to standard or PEG-IFN plus ribavirin (Brown 2007) .
In an open-label single-center study, 58 patients with chronic HCV were treated with a high-dose induction therapy with CIFN and ribavirin. The rationale for daily dosing in this study was based on the observation that serum levels of IFN-α given 3 times a week were dropping almost below the detection limit every other day and therefore reducing the antiviral capability. High initial dosing reduced the viral load even further and EVR yielded a higher SVR than 9 μg daily (Lam et al 1997) .
A more recent study compared the virologic response with CIFN or PEG-IFN-α-2b plus weight-based ribavirin in patients chronically infected with HCV genotype 1. The ITT analysis showed a response of 37% vs 41%, respectively, with response rates of 42% vs 44% observed in an analysis of the per-protocol population. Tolerability of the 2 treatment regimens was similar. In conclusion, both treatment regimens were safe and gave a similar antiviral response. If CIFN is administered daily rather than 3 times weekly, eradication of HCV could be achieved in a larger proportion of patients infected with HCV genotype 1 (Sjogren et al 2007) .
Even though enormous advances in treating patients with chronic hepatitis C have been achieved over the last decade (Cornberg et al 2007) , there is still a need for improved therapies, especially for the diffi cult-to-treat patients such as HCV genotype 1-infected individuals, patients with liver cirrhosis, or patients who did not respond to a previous IFN-α-based therapy (Shiffman 2004) . In an open label pilot study Cornberg et al (2007) investigated the effi cacy of CIFN plus ribavirin on viral kinetics, sustained virological response, and histological response in HCV non-responders. Seventy-seven patients were enrolled to receive CIFN given daily in combination with ribavirin 1000/1200 mg. An 8-week induction-dosing regimen of 18 μg CIFN, followed by 9 μg for 40 weeks was compared with 9 μg CIFN for 48 weeks. Ninety percent of patients were infected with HCV genotype 1. Overall, 82% of the patients demonstrated an EVR, 65% had an end of treatment response, and the SVR was 30%. IFN/ribavirn non-responders demonstrated a SVR of 22%. Induction dosing resulted in a greater fi rst-phase HCV RNA decay, which, however, did not translate to a better SVR, presumably due to more dose modifi cations. High ALT, younger age, and second-phase viral kinetics were associated with SVR. Only sustained responders and relapse patients showed an improved liver histology. In conclusion, daily dosing of CIFN plus ribavirin may be a promising concept for selected non-responders before considering therapies that are anti-viral but not curative. However, motivation and compliance are requisite and a CIFN induction is not required (Cornberg et al 2006) .
Despite advances in the therapy of chronic HCV, a large number of patients do not respond to current therapies. In an open-label, prospective, randomized, controlled study, 128 patients with chronic HCV were treated either with CIFN 15 μg tiw, plus ribavirin 1000 mg/day, or 3 MU IFN-α-2b tiw plus ribavirin 1000 mg/day for 48 weeks. The endpoint of the study was a SVR (defi ned as undetectable HCV RNA at 24 weeks post 48 weeks of treatment).
Overall, 57% of subjects in the CIFN/ribavirin group achieved a sustained viral response, compared with 40% of subjects in the IFN-α-2b/ribavirin group. In the subset of subjects with a high viral load, HCV RNA was successfully eradicated in more individuals who received CIFN/ribavirin than subjects who received IFN-α-2b/ribavirin (57 vs 31%). Among individuals with genotype 1 and high viral load, the sustained antiviral response was signifi cantly higher with CIFN/ribavirin than with IFN-α-2b/ribavirin (46 vs 14%). In conclusion, the study demonstrated that the combination of CIFN and ribavirin provides a signifi cantly better treatment response than the combination of IFN-α-2b and ribavirin in chronic HCV subjects infected with genotype 1 and high viral RNA load (Sjogren et al 2005) .
Recently, one study showed that daily dosing of 9 μg CIFN signifi cantly increased the SVR compared with a 9 μg tiw regimen (Rustgi et al 2005) . Preliminary data from a single center study suggested that daily dosing of CIFN in combination with ribavirin can achieve SVRs of 38%-45% in non-responders to standard IFN and ribavirin depending on the CIFN dose (Kaiser et al 2005) . High-dose-induction therapy seemed to further improve SVR in this study (Kaiser et al 2005) , even though it was not effective in studies with standard IFN-α-2a or -2b (Carithers et al 2000; Fried et al 2000; Hadziyannis et al 2001) . In a recent study it has been assessed that the fi rst-phase viral kinetics in 20 previously non-responders after a single dose of 15 μg or 30 μg CIFN and demonstrated a signifi cantly sharper decline (0.8 vs 1.5) of the HCV-RNA with the higher dose after 24 hours (Cotler et al 2003) . Sjogren et al (2005) have shown that combination therapy of CIFN and ribavirin provides a signifi cantly better treatment response compared with the combination of IFN-α-2b and ribavirin in chronic HCV subjects infected with genotype 1 and a high viral load.
Patients who failed prior treatment with IFN-α may benefit from a re-treatment with CIFN and ribavirin. One-hundred and three patients (69 non-responders and 34 relapsers) were randomly assigned to high-dose induction therapy (group A) (CIFN 27 μg → 9 μg daily for 24 weeks, 9 μg for 24 weeks) or low-dose-treatment (group B) (CIFN 18 μg tiw for 12 weeks, followed by 9 μg tiw for 36 weeks); each with ribavirin at 800 mg daily. Nonresponders treated with high-dose induction had a higher early virological response rate (63% vs 39%). The initial positive effect was lost during the last 24 weeks. Relapse patients revealed SVR in 70% and 38% in groups A and B. Treatment was well tolerated with side effect-related pre-term discontinuation in 8% and 5%. Viral elimination rates might be further increased by continuous daily administration of CIFN and weight-based ribavirin (Böcher et al 2006) .
We recently compared in a single center study the safety and effi cacy of high dose daily CIFN (18 μg daily for initially 8 weeks followed by 9 μg daily) plus ribavirin and PEG-IFN-α-2b plus ribavirin in therapy-naïve patients with chronic HCV infection . Treatment regimen with PEG-IFN-α-2a and ribavirin is superior for SVR and tolerablity. In genotype 1 the SVR was 58% vs 48%, and in genotype 2 and 3, 85% vs 73%, respectively. Side effects are more common and more severe in patients taking CIFN daily resulting in a higher drop out rate (15.4% vs 0%) and lower SVR. CIFN in combination with ribavirin might be favorable for diffi cult-to-treat patients with high viral load or non-response to conventional standard therapy. Patients with genotype 1 and low viral load (Ͻ800,000 IU/mL) did respond in both arms signfi cantly better to antiviral treatment compared with those with high viral load.
The side effects of IFN-α are farily similar: infl uenza-like symptoms, headache, cough, leucopenia and thrombocytopenia, hyper-or hypothyroidism, multiple effects on the immune system, and development of auto-antibodies. These side effects may sometimes be dose-dependent. Systemic sclerosis is an autoimmune disease that might be triggered by the IFN-α and may cause a stiffness of the skin but can affect the heart and the gastrointestinal tract as well. A few cases have been reported after the treatment of HCV with IFN-α-2a or 2b and also with IFN-alfacon-1 (Tahara et al 2007) .
Discussion
Combination of pegylated IFN-α-2a or 2b plus ribavirin is the gold standard in the therapy of chronic viral HCV infection. Most of the studies that have been reviewed are small in patient numbers and have dealt with IFN-alfacon-1 plus ribavirin alone, some have compared its effi cacy with that of IFN-α-2a plus ribavirin, but only a few trials have compared CIFN with the newer standard of care such as PEG-IFN-α-2a or 2b plus ribavirin.
But even with this newer pegylated regimen only 50% (eg, in genotype 1 and 4) or up to 80% (eg, in genotype 2 and 3) of patients will achieve a sustained virological response (Fried et al 2002) . However, comparing studies is always a problem. Defi ning the patient who is really a nonresponder to prior therapy or who was just not compliant makes a big difference. Adherence is an important factor for the success of the treatment (Fattovich et al 2003) . Therapies that induce severe side effects might in the end be less effective despite higher antiviral effi cacy. Head-to-head studies comparing PEG-IFN-α-2a or 2b plus ribavirin and CIFN plus ribavirin are completely lacking. Dosing of CIFN varies from country to country. In the US, CIFN is being used at concentrations of 15 μg tiw and in Germany 9 μg tiw is approved. However, these doses might be far too low to achieve a higher SVR rate in chronically infected patients. Because of the pharmacology and kinetics of CIFN, its serum levels change daily; high levels after subcutaneous injection are followed by a day of low serum concentrations. Even though CIFN shows a 10-fold stronger antiviral effect in vitro compared with IFN-α-2a (Sjogren et al 2007) , these kinetics are the major disadvantage of the 3-times-weekly treatment schedule with CIFN, giving the virus a chance to recover and multiply, and thus may lead to viral breakthrough or viral resistance. High-dose induction protocols with CIFN and ribavirin, using up to 27 μg daily, are quite promising but are associated with severe side effects, eg, infl uenza-like symptoms, myalgia, leucopenia, thrombocytopenia, neutropenia, depression, and weight loss, associated with higher drop-out rates and requiring dose modifi cations more often (Kaiser et al 2005; . Drug companies are aware of this shortcoming and strategies linking CIFN to a larger molecule like polyethylene glycol or albumin are under development. This formula may extend the stay of the molecule in the serum, and therefore enhance its antiviral capability and effi cacy. A once-weekly dosing of CIFN may increase compliance in patients, resulting in higher sustained virological response rates.
However, subcutaneous injection every other day followed by IFN-specifi c side effects such fever and infl uenze-like symptoms does not make CIFN a favorable drug for patients compared with PEG-IFNs. So far, CIFN given even at high-dose induction therapy in non-responders was well tolerated by treatment-experienced and motivated patients (Cornberg et al 2006) .
As expected, patients with advanced fi brosis or even cirrhosis showed low response, and these patients, who would benefi t most from curative antiviral treatment, have the worst outcome (Cornberg et al 2006) . These patients may benefi t from a low-dose IFN maintenance treatment to prevent complications of liver cirrhosis (Curry et al 2005; Erhardt et al 2007) .
Conclusion
PEG-IFNs plus ribavirin are standard of care for the treatment of naïve patients with chronic HCV infection, and long-term maintenance therapy with PEG-IFN might be the therapy of choice for cirrhotic patients (Kaiser et al 2005) .
However, selected and highly motivated patients with less fi brotic damage of the liver, and non-responders to previous therapy, may consider alternative therapies such as daily dosing of CIFN plus ribavirin in order to achieve sustained viral treatment, as long as a the pegylated formula of CIFN or polymerase or protease inhibitors are not available. CIFN has demonstrated effi cacy in the re-treatment of non-responders and relapsers. Although the optimal duration of treatment and the benefi ts and safety of maintenance therapy have not been determined, an extended duration is likely needed. The antiviral effi cacy of CIFN combined with a once-weekly injection of, for example, a PEG-CIFN plus ribavirin might be another therapeutic option in the near future.
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